Dr. Andrew J. Wagner

Emergency Medicine
1010 Three Springs Blvd, 
Durango, CO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
1010 Three Springs Blvd, 
Durango, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Wagner is an Emergency Medicine provider in Durango, Colorado. His top areas of expertise are Non-Muscle Invasive Bladder Cancer, Prostatectomy, and Penectomy. Dr. Wagner is currently accepting new patients.

His clinical research consists of co-authoring 138 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Emergency Medicine
Licenses
Emergency Medicine in OH
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID

Locations

1010 Three Springs Blvd, Durango, CO 81301

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Drug
Study Drugs: Olaratumab, Pembrolizumab
Study Phase: Phase 1
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: TP-1287
Study Phase: Phase 1
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)
Enrollment Status: Completed
Publish Date: August 31, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

138 Total Publications

How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.
Journal: Cancer treatment reviews
Published: June 13, 2025
Similar Doctors
Expertise in
1
conditions
Dr. Brett G. Ziercher
Emergency Medicine
Expertise in
1
conditions
Dr. Brett G. Ziercher
Emergency Medicine
801 W Maple St, 
Farmington, NM 
 (41.5 miles away)
505-325-5011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brett Ziercher is an Emergency Medicine provider in Farmington, New Mexico. Dr. Ziercher is highly rated in 1 condition, according to our data. His top areas of expertise are End-Stage Renal Disease (ESRD) and Liver Failure. Dr. Ziercher is currently accepting new patients.

Expertise in
1
conditions
Dr. Catherine A. Ambrose
Emergency Medicine
Expertise in
1
conditions
Dr. Catherine A. Ambrose
Emergency Medicine
801 W Maple St, 
Farmington, NM 
 (41.5 miles away)
505-609-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Catherine Ambrose is an Emergency Medicine provider in Farmington, New Mexico. Dr. Ambrose is highly rated in 1 condition, according to our data. Her top areas of expertise are End-Stage Renal Disease (ESRD) and Gallbladder Disease. Dr. Ambrose is currently accepting new patients.

Expertise in
1
conditions
Dr. Jenny R. Hargrove
Emergency Medicine
Expertise in
1
conditions
Dr. Jenny R. Hargrove
Emergency Medicine
801 W Maple St, 
Farmington, NM 
 (41.5 miles away)
505-609-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Jenny Hargrove is an Emergency Medicine provider in Farmington, New Mexico. Dr. Hargrove is highly rated in 1 condition, according to our data. Her top areas of expertise are End-Stage Renal Disease (ESRD) and Endoscopy. Dr. Hargrove is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wagner's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile